MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "COMT inhibitors"

  • 2022 International Congress

    The effect of co-administration of opicapone on the pharmacokinetics of levodopa

    D. Kamiyama, N. Nishikawa, G. Oyama, T. Hatano, N. Hattori (Tokyo, Japan)

    Objective: Few studies have examined levodopa (LD) pharmacokinetics in combination with opicapone (OPC) in Japanese patients with Parkinson's disease (PD). Therefore, we investigated changes in…
  • 2022 International Congress

    Opicapone use in patients with Parkinson’s disease with motor fluctuations: experience from a tertiary center

    E. Ojeda-Lepe, L. Muñoz-Delgado, S. Jesús, AD. Adarmes-Gómez, D. Macías-García, MV. Jiménez Jaraba, B. Benítez Zamora, F. Carrillo, P. Mir (Seville, Spain)

    Objective: To assess effectiveness and safety profile of Opicapone in our cohort of patients with Parkinson’s disease (PD) who received this treatment. Background: Opicapone is…
  • 2022 International Congress

    Effects of Once-Daily Opicapone 50 mg on COMT activity: A Pooled Post-hoc Analysis of Two Phase 1 Studies

    G. Loewen, A. Vijan, K. Olson, T. O'Reilly, G. Liang, O. Klepitskaya (San Dieg, USA)

    Objective: To assess the effects of opicapone (OPC) 50 mg adjunct to carbidopa/levodopa (CD/LD) on catechol-O-methyltransferase (COMT) activity by participants’ baseline characteristics using pooled data…
  • MDS Virtual Congress 2021

    Opicapone in Parkinson’s disease patients with early/simple motor fluctuations: real-world Spanish data

    M. Mata Alvarez-Santullano, C. Borrue Fernández, CM. Labandeira Guerra, T. Muñoz Ruiz, J. Abril Jamarillo, V. Gómez Mayordomo, PE. Bermejo Velasco (San Sebastián Reyes, Spain)

    Objective: To evaluate the efficacy and tolerability of opicapone in patients in Parkinson’s disease (PD) patients with early/simple motor fluctuations (E/S-MF) in the Spanish clinical…
  • MDS Virtual Congress 2021

    Opicapone in Parkinson’s Disease German Patients with Motor Fluctuations: Findings from the OPTIPARK Study

    H. Reichmann, A. Lees, D. Magalhães, J. Rocha, P. Soares-da-Silva (Dresden, Germany)

    Objective: To evaluate opicapone (OPC) when used in everyday clinical practice conditions to treat Parkinson’s disease (PD) patients with motor fluctuations. Background: OPC proved to…
  • MDS Virtual Congress 2021

    Efficacy of opicapone according to levodopa’s duration of use in Parkinson’s disease patients with motor fluctuations

    A. Antonini, G. Ebersbach, O. Rascol, D. Magalhaes, J. Rocha, P. Soares-da-Silva (Padova, Italy)

    Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuation (MF) according to levodopa’s duration of use. Background: OPC…
  • MDS Virtual Congress 2021

    Impact of 3-month earlier versus postponed initiation of opicapone versus entacapone in levodopa-treated patients with Parkinson’s disease and motor fluctuations

    C. Carroll, A. Lees, J. Ferreira, M. Fonseca, D. Magalhaes, J. Rocha, P. Soares-da-Silva (Plymouth, United Kingdom)

    Objective: This post-hoc analysis evaluated the impact of 3-month earlier versus postponed initiation of opicapone (OPC) in patients with Parkinson’s disease (PD) and motor fluctuations.…
  • MDS Virtual Congress 2021

    The OCEAN (OpiCapone Effect on motor fluctuations and associated pAiN) study in Parkinson’s disease: design and rationale of a randomized double-blind placebo-controlled trial

    K. Chaudhuri, P. Odin, J. Ferreira, A. Antonini, O. Rascol, M. Kurtis, A. Storch, K. Bannister, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: To evaluate if treatment with opicapone (OPC) in patients with Parkinson’s disease (PD) improves pain related to end-of-dose fluctuations, consequently improving patients’ well-being. Background:…
  • MDS Virtual Congress 2021

    The OASIS (OpicApone in Sleep dISorder) study in Parkinson’s disease: design and rationale of an open-label, single-arm, pilot trial

    R. Costa, C. Trenkwalder, J. Ferreira, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

    Objective: To evaluate the effects of opicapone (OPC) treatment on sleep disorders in patients with Parkinson’s disease (PD) and ‘wearing-off’. Background: OPC proved to be…
  • MDS Virtual Congress 2021

    Efficacy of opicapone according to different levodopa daily intakes in Parkinson’s disease patients with motor fluctuations

    G. Ebersbach, W. Poewe, J. Ferreira, D. Magalhaes, J. Rocha, P. Soares-da-Silva (Beelitz-Heilstätten, Germany)

    Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuation according to different levodopa daily intakes. Background: OPC proved…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Unusual prolonged survival in multiple system atrophy: A case report
  • An atypical and interesting feature of Parkinson´s disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley